We recorded 81 VC/PE transactions pertaining to the global life sciences sector for Nov 2020, aggregating to a sum of USD 4.7B. USA recorded 46 transactions for with total investment of USD 2.5B.
Around 67% of investment, spread over 40 transactions, went into supporting R&D stage companies. Vaccine companies continued to feature among top funding recipients; two vaccine companies from China – Sichuan Clover Biopharma and Recbio — pulled in USD555m between them.
The largest deal reported in the month was a USD750m round in National Resilience, Inc, a new company building an advanced biopharmaceutical manufacturing ecosystem. RESILIENCE has raised a total of over US$800 million of capital, including its Series A round of USD50m. This round was led by ARCH Venture Partners and 8VC with participation by GV and NEA
China reported investment of USD 1.05B over 13 VC/PE transactions. China also reported 3 IPOs aggregating a fundraise of USD1.2B, and 7 cross border transactions involving in/out licensing deals and other forms of research partnerships.
For 9m 2020, China’s biotech sector has received close to USD21B. Besides 13 VC transactions and 3 IPOs, China also reported 7 cross border in/outlicensing transactions/M&A transactions